Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transkaryotic plans hemophilia gene therapy trial in 1997 -- IPO prospectus.

Executive Summary

TRANSKARYOTIC HEMOPHILIA A GENE THERAPY SLATED FOR CLINICAL TRIALS IN 1997, the Cambridge, Mass.-based firm states in a recent prospectus for an initial public offering. Transkaryotic Therapies is developing a gene therapy product for "production and delivery of coagulation Factor VIII" in hemophilia A patients into clinical trials in 1997. The company has a nonexclusive license to Genetics Institute patents covering non-viral gene therapy with Factor VIII.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028910

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel